Clinical Trials List
2005-12-01 - 2007-11-01
Phase III
Terminated5
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
-
Trial Applicant
BAYER TAIWAN COMPANY LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 林宗哲 Division of Hematology & Oncology
- PEI-JER CHEN Digestive System Department
- Ann-Lii Cheng Division of Hematology & Oncology
- Chih-Hung Hsu Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- 李名陽 Division of Hematology & Oncology
- Tzeon-jye Chiou Division of Hematology & Oncology
- Peng-Chan Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Co-Principal Investigator
- Tsai-Sheng Yang Division of Hematology & Oncology
- Jen-Shi Chen Division of Hematology & Oncology
- 陳秉聰 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Stop recruiting
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
42 participants
-
Global
222 participants
